Archive | Life Sciences Industry Network RSS feed for this archive

The Life Sciences Industry Network provides pharma, biotech and life science companies with the environment to establish and maintain an internationally recognized industry standard of leadership and excellence.

PTC THERAPEUTICS EXPANDS INTERNATIONAL COMMERCIAL TEAM

SOUTH PLAINFIELD, NJ February 25, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC. Continue Reading     Advertisements

Continue Reading

Let Your Fingers Do the Walking?

BY SCOTT MAHNKEN If you were lucky enough to be one of the nine million that secured an Apple iPhone 5S kudos to you as you’re already experiencing the future of mobile authentication with Apple’s introduction of iTouch™. Continue Reading  

Continue Reading

N.J. company wins global entrepreneur of the year honor from IBM

By Emily Bader February 10, 2014 at 2:03 PM Camden-based Coriell Life Sciences, which focuses on storage, interpretation and delivery of genomic information for health care implementation, has won IBM’s entrepreneur of the year award at the global finals in San Francisco, the company announced Monday. Continue Reading

Continue Reading

Soligenix’s ThermoVax able to stabilize vaccines up to one year

Soligenix, a Princeton, New Jersey-based clinical stage biopharmaceutical company, announced positive results on Wednesday for a study involving its vaccine heat stabilization technology, ThermoVax. Continue Reading

Continue Reading

Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Receipt of Proceeds increases January Cash Position to Approximately $6.6 million Princeton, NJ – January 16, 2014 – Soligenix, Inc. (OTCQB: SNGX)  (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and […]

Continue Reading

Opening of the Biotechnology and Drug-Discovery Laboratory at the Stevens Institute of Technology

The Center for Healthcare Innovation at Stevens Institute of Technology announces the opening of the Biotechnology and Drug-Discovery Laboratory (http://www.stevens.edu/chi/biotech). The lab will open January 2014 as a new biotechnology and drug discovery enterprise that will partner with other Stevens faculty, students and external academic and industry collaborators.    Established in part with a generous […]

Continue Reading

Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax™ Vaccine Heat Stabilization Technology

Milestone Achieved under $9.4 Million NIAID Cooperative Grant   Princeton, NJ – January 15, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced […]

Continue Reading

Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

Princeton, NJ – January 6, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as […]

Continue Reading

PTC THERAPEUTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

SOUTH PLAINFIELD, NJ – December 23, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to the market open today. Continue Reading

Continue Reading

East Brunswick Tech Firm to Share in $60 Million Statewide Grant

East Brunswick’s Savient Pharmaceuticals previously developed a drug to treat resistant chronic gout. Posted by Davy James (Editor) , December 19, 2013 at 03:01 PM Continue Reading

Continue Reading